A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis: Comment on the article by Maksymowych et al
Open Access
- 4 February 2003
- journal article
- letter
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (2), 583-584
- https://doi.org/10.1002/art.10717
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- A six‐month randomized, controlled, double‐blind, dose‐response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitisArthritis & Rheumatism, 2002
- Prolonged, Symptomatic Hypocalcemia with Pamidronate Administration and Subclinical HypoparathyroidismEndocrine, 2001
- Symptomatic hypocalcaemia following intravenous pamidronate in cancer patientsAustralian and New Zealand Journal of Medicine, 1999
- Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemiaClinical Oncology, 1998
- Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.Journal of Clinical Oncology, 1996
- Electrocardiographic Q-Tc prolongation associated with infusion of intravenous pamidronate disodiumHeart, 1993